Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 20.72 AUD -1.15% Market Closed
Updated: May 31, 2024
Section:
 

Relative Value

The Relative Value of one NEU stock under the Base Case scenario is hidden AUD. Compared to the current market price of 20.72 AUD, Neuren Pharmaceuticals Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NEU Relative Value
HIDDEN
Unlock
Worst Case
Base Case
Best Case

Valuation Multiples

11.1
P/S
P/S
Price to Sales
11.1
vs History
87
vs Industry
15
Median 3Y
147.8
Median 5Y
153.3
Industry
2.4
Forward
17.2
More Details
16.8
P/E
P/E
Price to Earnings
16.8
vs History
28
vs Industry
28
Median 3Y
-15.2
Median 5Y
-16.3
Industry
22.8
Forward
28.6
More Details
14.3
P/OCF
P/OCF
Price to OCF
14.3
vs History
38
vs Industry
29
Median 3Y
-18.4
Median 5Y
-13.1
Industry
17
More Details
14.3
P/FCFE
P/FCFE
Price to FCFE
14.3
vs History
38
vs Industry
26
Median 3Y
-18.4
Median 5Y
-13.1
Industry
23.2
More Details
12.9
P/B
P/B
Price to Book Value
12.9
vs History
50
vs Industry
5
Median 3Y
14.4
Median 5Y
13.1
Industry
2.1
More Details
10.1
EV/S
EV/S
Enterprise Value to Sales
10.1
vs History
87
vs Industry
14
Median 3Y
136.5
Median 5Y
141.9
Industry
2.6
Forward
15.7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.1
More Details
11.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.8
vs History
28
vs Industry
30
Median 3Y
-19.1
Median 5Y
-14.6
Industry
13.5
Forward
20.2
More Details
11.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.8
vs History
28
vs Industry
35
Median 3Y
-19.1
Median 5Y
-14.6
Industry
16.9
Forward
22.9
More Details
13
EV/OCF
EV/OCF
Enterprise Value to OCF
13
vs History
38
vs Industry
31
Median 3Y
-15.5
Median 5Y
-12.1
Industry
15.8
More Details
13
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
13
vs History
38
vs Industry
26
Median 3Y
-15.4
Median 5Y
-12.1
Industry
17.7
More Details
150.4
EV/IC
EV/IC
Enterprise Value to IC
150.4
vs History
58
vs Industry
1
Median 3Y
180.4
Median 5Y
177.4
Industry
1.9
More Details

Multiples Across Competitors

NEU Competitors Multiples
Neuren Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Neuren Pharmaceuticals Ltd
ASX:NEU
2.6B AUD 11.1 16.8 11.8 11.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
773.6B USD 21.5 126 61.6 70.1
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 16.7 45.8 34.1 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
349.6B USD 4.1 9.1 11.2 14.6
US
Merck & Co Inc
NYSE:MRK
315.5B USD 5.1 136.8 34.2 55.8
UK
AstraZeneca PLC
LSE:AZN
186.5B GBP 5 37.4 174.5 278.3
CH
Roche Holding AG
SIX:ROG
182B CHF 3.1 15.8 9 10.7
CH
Novartis AG
SIX:NOVN
178.4B CHF 3.4 11.3 8.6 12.5
US
Pfizer Inc
NYSE:PFE
159.8B USD 2.9 -517.2 12.6 20.3
P/E Multiple
Earnings Growth
AU
Neuren Pharmaceuticals Ltd
ASX:NEU
Average P/E: 49.9
16.8
5%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
126
364%
DK
Novo Nordisk A/S
CSE:NOVO B
45.8
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.1
-21%
US
Merck & Co Inc
NYSE:MRK
136.8
7 598%
UK
AstraZeneca PLC
LSE:AZN
37.4
175%
CH
Roche Holding AG
SIX:ROG
15.8
28%
CH
Novartis AG
SIX:NOVN
11.3
17%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -517.2
683%

See Also

Summary
NEU intrinsic value, competitors valuation, and company profile.
DCF Valuation
NEU stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NEU stock valuation using valuation multiples.
Wall Street Estimates
NEU price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NEU stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 142,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.